Bio-Rad Laboratories (BIO) Net Income towards Common Stockholders (2009 - 2026)

Bio-Rad Laboratories (BIO) has reported Net Income towards Common Stockholders for 18 consecutive years, with -$527.1 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Net Income towards Common Stockholders fell 923.59% year-over-year to -$527.1 million; the TTM figure through Mar 2026 stood at $168.8 million (up 107.8% YoY), while the FY2025 annual figure was $759.9 million, up 141.2% from the prior year.
• Net Income towards Common Stockholders slipped to -$527.1 million in Q1 2026 per BIO's latest filing, from $720.0 million in the prior quarter.
• Across five years, Net Income towards Common Stockholders topped out at $827.8 million in Q4 2022 and bottomed at -$3.4 billion in Q1 2022.
• Historically, Net Income towards Common Stockholders has averaged -$345.7 million across 5 years, with a median of $64.0 million in 2025.
• Annual changes were most pronounced in 2024 — Net Income towards Common Stockholders jumped 514.74% — and 2026, when it tumbled 923.59%.
• Bio-Rad Laboratories' Net Income towards Common Stockholders stood at $827.8 million in 2022, then tumbled by 57.75% to $349.7 million in 2023, then tumbled by 304.67% to -$715.8 million in 2024, then surged by 200.59% to $720.0 million in 2025, then slumped by 173.21% to -$527.1 million in 2026.
• Business Quant data shows BIO's Net Income towards Common Stockholders at -$527.1 million in Q1 2026, $720.0 million in Q4 2025, and -$341.9 million in Q3 2025.